Millennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA)

Millennium Management LLC lifted its position in Savara Inc (NASDAQ:SVRA) by 71.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 482,263 shares of the company’s stock after purchasing an additional 201,599 shares during the quarter. Millennium Management LLC owned approximately 0.28% of Savara worth $1,481,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in SVRA. Vanguard Group Inc. lifted its position in Savara by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock worth $25,512,000 after acquiring an additional 365,959 shares during the period. SG Americas Securities LLC increased its stake in Savara by 14.0% in the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock valued at $158,000 after purchasing an additional 6,330 shares in the last quarter. Geode Capital Management LLC increased its stake in Savara by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company’s stock valued at $8,549,000 after purchasing an additional 57,187 shares in the last quarter. Deutsche Bank AG increased its stake in Savara by 6.1% in the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company’s stock valued at $2,848,000 after purchasing an additional 53,054 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its position in Savara by 314.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company’s stock worth $217,000 after buying an additional 53,547 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Guggenheim reissued a “buy” rating and set a $8.00 price target (down previously from $9.00) on shares of Savara in a research report on Wednesday, May 28th. HC Wainwright downgraded Savara from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $6.00 to $2.00 in a research report on Thursday, May 29th. Evercore ISI lowered their price target on Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research report on Wednesday, May 28th. Finally, Wells Fargo & Company decreased their target price on Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.17.

Savara Stock Performance

NASDAQ:SVRA opened at $2.40 on Wednesday. The business’s 50-day simple moving average is $2.90 and its 200 day simple moving average is $2.93. Savara Inc has a one year low of $1.89 and a one year high of $5.11. The stock has a market cap of $414.81 million, a price-to-earnings ratio of -5.58 and a beta of 0.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). As a group, sell-side analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.